一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Pembrolizumab；sac-TMT；Carboplatin；Paclitaxel；Nab-paclitaxel，当前状态为招募中。登记地点显示中国北京、重庆、福州、厦门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pembrolizumab；sac-TMT；Carboplatin；Paclitaxel；Nab-paclitaxel · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital ( Site 2411) · 北京
- Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2410) · 北京
- Peking Union Medical College Hospital ( Site 2412) · 北京
- Army Medical Center of People's Liberation Army-respiratory ( Site 2426) · 重庆
- Fujian Provincial Cancer Hospital ( Site 2419) · 福州
- The First Affiliated hospital of Xiamen University-oncology ( Site 2420) · 厦门
- The First Affiliated Hospital of Guangzhou Medical University ( Site 2417) · 广州
- Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 2416) · 广州
- Harbin Medical University Cancer Hospital-oncology of department ( Site 2415) · 哈尔滨
- Henan Cancer Hospital-Pneumology department ( Site 2423) · 郑州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 2424) · 武汉
- The Second Xiangya Hospital of Central South University-Oncology ( Site 2418) · 长沙
- First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 2402) · 淮安
- Northern Jiangsu People's Hospital-General Surgery Department ( Site 2403) · 扬州
- The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2405) · 南昌
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 2404) · 南昌
- Jilin Province Tumor Hospital-GCP office ( Site 2413) · 长春
- The First Hospital of Jilin University-Oncology ( Site 2414) · 长春
- Shanghai East Hospital ( Site 2428) · 上海
- Shanghai Pulmonary Hospital ( Site 2427) · 上海
- West China Hospital, Sichuan University ( Site 2422) · 成都
- Sichuan Cancer hospital. ( Site 2421) · 成都
- The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 2425) · 乌鲁木齐
- The first Affiliated Hospital, Zhejiang University School of Medicine-Respiratory Department ( Site 2406) · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 2407) · 杭州
- Zhejiang Cancer Hospital-Breast Oncology ( Site 2408) · 杭州
- Taizhou Hospital of Zhejiang Province ( Site 2430) · 台州
- The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 2409) · 温州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\]
- * Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology
- * Has life expectancy ≥3 months
- * Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation
- * Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided
- * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
- * Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation
- * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06422143；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。